Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries
The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse. To determin...
Saved in:
| Published in: | JAMA : the journal of the American Medical Association Vol. 324; no. 15; p. 1532 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
20.10.2020
|
| Subjects: | |
| ISSN: | 1538-3598, 1538-3598 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse.
To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries.
Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening.
World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics.
Self-report of having ever had a screening test for cervical cancer.
Of the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened.
In this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening. |
|---|---|
| AbstractList | The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse.ImportanceThe World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse.To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries.ObjectiveTo determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries.Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening.Design, Setting, and ParticipantsAnalysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening.World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics.ExposuresWorld region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics.Self-report of having ever had a screening test for cervical cancer.Main Outcomes and MeasuresSelf-report of having ever had a screening test for cervical cancer.Of the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened.ResultsOf the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened.In this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening.Conclusions and RelevanceIn this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening. The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low- and middle-income countries (LMICs) is sparse. To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries. Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1 136 289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening. World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics. Self-report of having ever had a screening test for cervical cancer. Of the 1 129 404 women included in the analysis, 542 475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened. In this cross-sectional study of data collected in 55 low- and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening. |
| Author | Atun, Rifat Chen, Simiao Theilmann, Michaela Sturua, Lela Manne-Goehler, Jennifer Lemp, Julia M Farzadfar, Farshad Davies, Justine I Houehanou, Corine Gurung, Mongal S Kibachio, Joseph M Bussmann, Hermann Gathecha, Gladwell Moghaddam, Sahar Saeedi Houinato, Dismand Marcus, Maja-Emilia Dryden-Peterson, Scott Tsabedze-Sibanyoni, Lindiwe Bärnighausen, Till De Neve, Jan-Walter Martins, Joao S Probst, Charlotte Ebert, Cara Vollmer, Sebastian Geldsetzer, Pascal |
| Author_xml | – sequence: 1 givenname: Julia M surname: Lemp fullname: Lemp, Julia M organization: Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany – sequence: 2 givenname: Jan-Walter surname: De Neve fullname: De Neve, Jan-Walter organization: Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany – sequence: 3 givenname: Hermann surname: Bussmann fullname: Bussmann, Hermann organization: Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany – sequence: 4 givenname: Simiao surname: Chen fullname: Chen, Simiao organization: Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing – sequence: 5 givenname: Jennifer surname: Manne-Goehler fullname: Manne-Goehler, Jennifer organization: Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston – sequence: 6 givenname: Michaela surname: Theilmann fullname: Theilmann, Michaela organization: Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany – sequence: 7 givenname: Maja-Emilia surname: Marcus fullname: Marcus, Maja-Emilia organization: Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany – sequence: 8 givenname: Cara surname: Ebert fullname: Ebert, Cara organization: RWI-Leibniz Institute for Economic Research, Essen (Berlin office), Germany – sequence: 9 givenname: Charlotte surname: Probst fullname: Probst, Charlotte organization: Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada – sequence: 10 givenname: Lindiwe surname: Tsabedze-Sibanyoni fullname: Tsabedze-Sibanyoni, Lindiwe organization: Eswatini Ministry of Health, Mbabane, Eswatini – sequence: 11 givenname: Lela surname: Sturua fullname: Sturua, Lela organization: Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia – sequence: 12 givenname: Joseph M surname: Kibachio fullname: Kibachio, Joseph M organization: Institute of Global Health, Faculty of Medicine, University of Geneva (UNIGE), Geneva, Switzerland – sequence: 13 givenname: Sahar Saeedi surname: Moghaddam fullname: Moghaddam, Sahar Saeedi organization: Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran – sequence: 14 givenname: Joao S surname: Martins fullname: Martins, Joao S organization: Faculty of Medicine and Health Sciences, Universidade Nacional Timor Lorosa'e, Rua Jacinto Candido, Dili, Timor-Leste – sequence: 15 givenname: Dismand surname: Houinato fullname: Houinato, Dismand organization: Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin – sequence: 16 givenname: Corine surname: Houehanou fullname: Houehanou, Corine organization: Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin – sequence: 17 givenname: Mongal S surname: Gurung fullname: Gurung, Mongal S organization: Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan – sequence: 18 givenname: Gladwell surname: Gathecha fullname: Gathecha, Gladwell organization: Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya – sequence: 19 givenname: Farshad surname: Farzadfar fullname: Farzadfar, Farshad organization: Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran – sequence: 20 givenname: Scott surname: Dryden-Peterson fullname: Dryden-Peterson, Scott organization: Botswana Harvard AIDS Institute, Gaborone, Botswana – sequence: 21 givenname: Justine I surname: Davies fullname: Davies, Justine I organization: Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom – sequence: 22 givenname: Rifat surname: Atun fullname: Atun, Rifat organization: Department of Global Health and Social Medicine at the Harvard Medical School, Boston, Massachusetts – sequence: 23 givenname: Sebastian surname: Vollmer fullname: Vollmer, Sebastian organization: Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany – sequence: 24 givenname: Till surname: Bärnighausen fullname: Bärnighausen, Till organization: Africa Health Research Institute, Somkhele, South Africa – sequence: 25 givenname: Pascal surname: Geldsetzer fullname: Geldsetzer, Pascal organization: Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33079153$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1LxDAUDKK4H3r2Jjl66ZomTds9SvFjoaKg4rG8Ji-SpU3XpF3x3xtwBd_lzcwbBuYtyLEbHBJykbJVylh6vYUeVpzxSHOeZUdknkpRJkKuy-N_eEYWIWxZnFQUp2QmBCvW8Ton77U1ONoe6bPHPXToFNLB0Ar93iroaAVR8fRFeURn3Qe1jkpJ6-EroeA0fbRad5hsnBpiSDVMbvQWwxk5MdAFPD_sJXm7u32tHpL66X5T3dQJSJaPCeRCQtEqVrA2x4xxKKVMM5nnRgK0RmmFGJvxDEoUmcECQUiuy7XSAo3mS3L1m7vzw-eEYWx6GxR2HTgcptDwTHLJiiLl0Xp5sE5tj7rZeduD_27-nsF_AMELYp0 |
| CitedBy_id | crossref_primary_10_1155_2022_2028082 crossref_primary_10_1177_10732748251330698 crossref_primary_10_26633_RPSP_2025_44 crossref_primary_10_1200_GO_22_00407 crossref_primary_10_1371_journal_pone_0325131 crossref_primary_10_3389_fonc_2023_1105468 crossref_primary_10_1111_cas_15723 crossref_primary_10_1177_11786329251337851 crossref_primary_10_1093_jnci_djac189 crossref_primary_10_1007_s43032_024_01477_z crossref_primary_10_1136_bmjopen_2023_074020 crossref_primary_10_1136_bmjopen_2023_078466 crossref_primary_10_1186_s12889_025_23143_y crossref_primary_10_1016_j_lana_2021_100036 crossref_primary_10_1002_ijgo_14395 crossref_primary_10_3390_cancers16203541 crossref_primary_10_1016_j_respe_2023_101845 crossref_primary_10_3389_fmed_2022_843262 crossref_primary_10_1016_j_canlet_2021_10_036 crossref_primary_10_1002_tox_24265 crossref_primary_10_1007_s10900_024_01395_w crossref_primary_10_1016_j_bios_2023_115968 crossref_primary_10_1093_ije_dyac125 crossref_primary_10_1001_jama_2020_25217 crossref_primary_10_2196_51477 crossref_primary_10_1001_jama_2020_25214 crossref_primary_10_1038_s41591_023_02315_6 crossref_primary_10_33590_emj_GMJC4983 crossref_primary_10_1016_j_asoc_2024_112202 crossref_primary_10_3390_cancers14112612 crossref_primary_10_1093_oncolo_oyaf197 crossref_primary_10_1136_bmjopen_2022_062556 crossref_primary_10_1136_bmjopen_2022_069616 crossref_primary_10_3390_ijerph19148237 crossref_primary_10_1007_s10735_025_10396_5 crossref_primary_10_1016_j_intimp_2025_114124 crossref_primary_10_3389_fonc_2021_724832 crossref_primary_10_54235_27382737_2023_v3_2_36 crossref_primary_10_26633_RPSP_2022_107 crossref_primary_10_1007_s12032_024_02582_4 crossref_primary_10_1093_ajcp_aqae103 crossref_primary_10_3748_wjg_v28_i21_2361 crossref_primary_10_1158_1940_6207_CAPR_20_0571 crossref_primary_10_1186_s12885_022_10331_x crossref_primary_10_1186_s12885_022_10395_9 crossref_primary_10_1186_s12905_023_02553_3 crossref_primary_10_1186_s12885_024_12789_3 crossref_primary_10_1097_CR9_0000000000000027 crossref_primary_10_1016_j_snb_2024_135295 crossref_primary_10_3390_s22093272 crossref_primary_10_1016_j_ijgc_2024_100008 crossref_primary_10_1080_21642850_2022_2136184 crossref_primary_10_1136_bmjopen_2021_058026 crossref_primary_10_1111_1471_0528_16758 crossref_primary_10_1200_GO_23_00385 crossref_primary_10_3389_fgwh_2025_1467313 crossref_primary_10_1038_s41591_023_02288_6 crossref_primary_10_3322_caac_21660 crossref_primary_10_1002_jia2_26090 crossref_primary_10_1371_journal_pmed_1004143 crossref_primary_10_1016_j_cyto_2024_156782 crossref_primary_10_1016_S1470_2045_22_00704_5 crossref_primary_10_1007_s10495_023_01840_6 crossref_primary_10_3390_app13021061 crossref_primary_10_1136_bmjopen_2023_081282 crossref_primary_10_1186_s12889_024_19917_5 crossref_primary_10_7759_cureus_69136 crossref_primary_10_1016_j_vaccine_2022_08_020 crossref_primary_10_1186_s12885_025_13926_2 crossref_primary_10_1002_cncr_35289 crossref_primary_10_1002_hsr2_70295 crossref_primary_10_2217_epi_2022_0396 crossref_primary_10_2147_RMHP_S296914 crossref_primary_10_1136_bmjopen_2022_068212 crossref_primary_10_1186_s12905_021_01272_x crossref_primary_10_1016_j_rechem_2025_102720 crossref_primary_10_1371_journal_pone_0258539 crossref_primary_10_3389_fpubh_2022_981383 crossref_primary_10_1590_1413_812320212610_11352021 crossref_primary_10_1097_PAI_0000000000001226 crossref_primary_10_3390_antiox12020317 crossref_primary_10_3390_medicina58020306 crossref_primary_10_1002_ijgo_13879 crossref_primary_10_1186_s12885_023_10927_x crossref_primary_10_1016_j_heliyon_2023_e18011 crossref_primary_10_3390_v16091357 crossref_primary_10_1177_1073274821997497 crossref_primary_10_1186_s12992_022_00890_w crossref_primary_10_7189_jogh_14_04189 crossref_primary_10_1097_QCO_0000000000000805 crossref_primary_10_32635_2176_9745_RBC_2023v69n3_3993 crossref_primary_10_1016_j_gore_2024_101355 crossref_primary_10_3389_fpubh_2021_670032 crossref_primary_10_2147_IJWH_S374487 crossref_primary_10_3390_v16050680 crossref_primary_10_1136_bmjopen_2023_082918 crossref_primary_10_1007_s10552_025_02058_4 crossref_primary_10_1080_16549716_2025_2491852 crossref_primary_10_1177_21501319231198942 crossref_primary_10_1186_s12905_022_01777_z crossref_primary_10_3389_fimmu_2025_1612761 crossref_primary_10_1186_s12879_025_10485_6 crossref_primary_10_1007_s40944_025_00971_9 crossref_primary_10_7189_jogh_11_04036 crossref_primary_10_1136_bmjgh_2024_018634 crossref_primary_10_1186_s12885_025_14465_6 crossref_primary_10_1186_s12916_023_02840_8 crossref_primary_10_1177_20503121231225935 crossref_primary_10_1200_OP_22_00156 crossref_primary_10_1177_10732748211026670 crossref_primary_10_1038_s41467_025_58875_3 crossref_primary_10_2188_jea_JE20240065 crossref_primary_10_3389_fonc_2022_979884 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jama.2020.16244 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-3598 |
| ExternalDocumentID | 33079153 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NIA NIH HHS grantid: P01 AG041710 – fundername: NIAID NIH HHS grantid: R01 AI112339 – fundername: Wellcome Trust – fundername: NIAID NIH HHS grantid: T32 AI007433 – fundername: NIA NIH HHS grantid: R01 AG034479 – fundername: NCI NIH HHS grantid: R01 CA236546 – fundername: NIA NIH HHS grantid: R21 AG034263 – fundername: NCATS NIH HHS grantid: KL2 TR003143 – fundername: FIC NIH HHS grantid: D43 TW009775 |
| GroupedDBID | --- -ET -~X .55 .XZ 0R~ 0WA 186 18M 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQQT AAWTL ABBLC ABCQX ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACGFS ACNCT ACPRK ACQAM ADBBV ADUKH AFCHL AFFNX AFRAH AGFXO AGHSJ AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BKOMP BRYMA C45 CGR CJ0 CS3 CUY CVF EAM EBD EBS ECM EIF EJD EMOBN EX3 F5P GX1 H13 HF~ KOO KQ8 L7B MVM N4W N9A NEJ NPM NYF OBH OCB OGEVE OHH OK1 OMK OVD P2P PKN PQQKQ QJJ RAJ RNS SJN SV3 TEORI TN5 UHB UIG UKR UPT VVN WH7 WOW X7M XHN XSW XZL YCJ YFH YIF YIN YOC YPV YQT YQY YR2 YR5 YSK YYM YZZ ZCA ~H1 7X8 ACAHW ADXHL AETEA ARBJA |
| ID | FETCH-LOGICAL-a506t-a635a7bc070b6e402a85514566f5aabfcdcee62424a8e34fe7ea352d89cd3efd2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 124 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000590158900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-3598 |
| IngestDate | Thu Sep 04 16:31:04 EDT 2025 Wed Feb 19 02:05:29 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a506t-a635a7bc070b6e402a85514566f5aabfcdcee62424a8e34fe7ea352d89cd3efd2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://jamanetwork.com/journals/jama/articlepdf/2771901/jama_lemp_2020_oi_200096_1602876073.00844.pdf |
| PMID | 33079153 |
| PQID | 2452507712 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2452507712 pubmed_primary_33079153 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-20 20201020 |
| PublicationDateYYYYMMDD | 2020-10-20 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA : the journal of the American Medical Association |
| PublicationTitleAlternate | JAMA |
| PublicationYear | 2020 |
| References | 33620396 - JAMA. 2021 Feb 23;325(8):790 |
| References_xml | – reference: 33620396 - JAMA. 2021 Feb 23;325(8):790 |
| SSID | ssj0000137 |
| Score | 2.6504967 |
| Snippet | The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1532 |
| SubjectTerms | Adult Cross-Sectional Studies Developing Countries Early Detection of Cancer - statistics & numerical data Female Global Health Health Care Surveys Humans Middle Aged Patient Acceptance of Health Care - statistics & numerical data Self Report Uterine Cervical Neoplasms - diagnosis |
| Title | Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33079153 https://www.proquest.com/docview/2452507712 |
| Volume | 324 |
| WOSCitedRecordID | wos000590158900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6mPcmJ5Fi8dCWgoq9hdkX9JLUpurfd2abohdB8BLIYZcwO48vMzvfMHaTyCSJrS2ECQMrEBErkTubCg1aRQlEYZaDHzYhR6N8MinGbcKtaa9Vrnyid9Sm1pQjv418AU7KMLqbvQmaGkXV1XaExjrrxAhlSKvlJP9BH-U5M71RE1Pditrnm3UowtcMI9zv-NLHmf7uf79wj-20CJPfL1Vin63Z6oBtDdsa-iF7HUydpZHynOibwDcd8drxnvcauLJHijDnT5qu5GBk49OKpykf1J-CQ2X40Oc0BHqWGjehpnYaytUcsZf-w3PvUbTjFQSkQbYQgFgDpNJo9Cqz-B8JOcEnxHcuBVBOGwygvn0EchsnzkoLCNdMXmgTW2eiY7ZR1ZU9ZdxQg2qoEpWnKonBQmHQzkPjlJUQSOiy65XISlRfqklAZev3pvwWWpedLOVezpY8G2WM_qfAwzv7w-pztk2nSVElCi5Yx6Hx2ku2qT8W02Z-5fUCn6Px8AsQL8Ig |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lifetime+Prevalence+of+Cervical+Cancer+Screening+in+55+Low-+and+Middle-Income+Countries&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=Lemp%2C+Julia+M&rft.au=De+Neve%2C+Jan-Walter&rft.au=Bussmann%2C+Hermann&rft.au=Chen%2C+Simiao&rft.date=2020-10-20&rft.eissn=1538-3598&rft.volume=324&rft.issue=15&rft.spage=1532&rft_id=info:doi/10.1001%2Fjama.2020.16244&rft_id=info%3Apmid%2F33079153&rft_id=info%3Apmid%2F33079153&rft.externalDocID=33079153 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-3598&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-3598&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-3598&client=summon |